Ruxolitinib treatment for GvHD in patients with myelofibrosis

Y. Mori, K. Ikeda, T. Inomata, G. Yoshimoto, Nobuharu Fujii, H. Ago, T. Teshima

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibrosis often induces 'withdrawal syndrome' characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD. Four patients with GvHD (one acute and three chronic) after SCT for myelofibrosis were treated with ruxolitinib. Low-dose ruxolitinib at 5 mg/day was safe and effective, but one of two patients treated at 10 mg/day of ruxolitinib was complicated with severe cytopenia. Withdrawal syndrome developed in one patient, who died of recurrence of GvHD shortly after discontinuation of ruxolitinib. Slow tapering or maintenance with low-dose ruxolitinib inhibited GvHD flare. Our experience calls attention that initiation at low-dose of ruxolitinib may be safe and careful tapering schedule is required to avoid withdrawal syndrome in patients with GvHD after SCT for myelofibrosis.

Original languageEnglish
Pages (from-to)1584-1587
Number of pages4
JournalBone Marrow Transplantation
Volume51
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Primary Myelofibrosis
Therapeutics
Stem Cell Transplantation
Appointments and Schedules
INCB018424
Recurrence
Hematopoietic Stem Cell Transplantation
Acute Disease
Steroids
Maintenance

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Mori, Y., Ikeda, K., Inomata, T., Yoshimoto, G., Fujii, N., Ago, H., & Teshima, T. (2016). Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplantation, 51(12), 1584-1587. https://doi.org/10.1038/bmt.2016.256

Ruxolitinib treatment for GvHD in patients with myelofibrosis. / Mori, Y.; Ikeda, K.; Inomata, T.; Yoshimoto, G.; Fujii, Nobuharu; Ago, H.; Teshima, T.

In: Bone Marrow Transplantation, Vol. 51, No. 12, 01.12.2016, p. 1584-1587.

Research output: Contribution to journalArticle

Mori, Y, Ikeda, K, Inomata, T, Yoshimoto, G, Fujii, N, Ago, H & Teshima, T 2016, 'Ruxolitinib treatment for GvHD in patients with myelofibrosis', Bone Marrow Transplantation, vol. 51, no. 12, pp. 1584-1587. https://doi.org/10.1038/bmt.2016.256
Mori, Y. ; Ikeda, K. ; Inomata, T. ; Yoshimoto, G. ; Fujii, Nobuharu ; Ago, H. ; Teshima, T. / Ruxolitinib treatment for GvHD in patients with myelofibrosis. In: Bone Marrow Transplantation. 2016 ; Vol. 51, No. 12. pp. 1584-1587.
@article{803dd627df0040d9a845978348ba19cc,
title = "Ruxolitinib treatment for GvHD in patients with myelofibrosis",
abstract = "Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibrosis often induces 'withdrawal syndrome' characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD. Four patients with GvHD (one acute and three chronic) after SCT for myelofibrosis were treated with ruxolitinib. Low-dose ruxolitinib at 5 mg/day was safe and effective, but one of two patients treated at 10 mg/day of ruxolitinib was complicated with severe cytopenia. Withdrawal syndrome developed in one patient, who died of recurrence of GvHD shortly after discontinuation of ruxolitinib. Slow tapering or maintenance with low-dose ruxolitinib inhibited GvHD flare. Our experience calls attention that initiation at low-dose of ruxolitinib may be safe and careful tapering schedule is required to avoid withdrawal syndrome in patients with GvHD after SCT for myelofibrosis.",
author = "Y. Mori and K. Ikeda and T. Inomata and G. Yoshimoto and Nobuharu Fujii and H. Ago and T. Teshima",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/bmt.2016.256",
language = "English",
volume = "51",
pages = "1584--1587",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Ruxolitinib treatment for GvHD in patients with myelofibrosis

AU - Mori, Y.

AU - Ikeda, K.

AU - Inomata, T.

AU - Yoshimoto, G.

AU - Fujii, Nobuharu

AU - Ago, H.

AU - Teshima, T.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibrosis often induces 'withdrawal syndrome' characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD. Four patients with GvHD (one acute and three chronic) after SCT for myelofibrosis were treated with ruxolitinib. Low-dose ruxolitinib at 5 mg/day was safe and effective, but one of two patients treated at 10 mg/day of ruxolitinib was complicated with severe cytopenia. Withdrawal syndrome developed in one patient, who died of recurrence of GvHD shortly after discontinuation of ruxolitinib. Slow tapering or maintenance with low-dose ruxolitinib inhibited GvHD flare. Our experience calls attention that initiation at low-dose of ruxolitinib may be safe and careful tapering schedule is required to avoid withdrawal syndrome in patients with GvHD after SCT for myelofibrosis.

AB - Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibrosis often induces 'withdrawal syndrome' characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD. Four patients with GvHD (one acute and three chronic) after SCT for myelofibrosis were treated with ruxolitinib. Low-dose ruxolitinib at 5 mg/day was safe and effective, but one of two patients treated at 10 mg/day of ruxolitinib was complicated with severe cytopenia. Withdrawal syndrome developed in one patient, who died of recurrence of GvHD shortly after discontinuation of ruxolitinib. Slow tapering or maintenance with low-dose ruxolitinib inhibited GvHD flare. Our experience calls attention that initiation at low-dose of ruxolitinib may be safe and careful tapering schedule is required to avoid withdrawal syndrome in patients with GvHD after SCT for myelofibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84990909798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990909798&partnerID=8YFLogxK

U2 - 10.1038/bmt.2016.256

DO - 10.1038/bmt.2016.256

M3 - Article

C2 - 27721370

AN - SCOPUS:84990909798

VL - 51

SP - 1584

EP - 1587

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -